HERO MASTER PAGE

Curasight

Revolutionizing cancer discovery

Introduction

Curasight has developed a revolutionary way of identifying cancer indicators, minimising the side effects of traditional cancer treatment. By using PET-scanning, Curasight targets the urokinase-type plasminogen activator receptor (uPAR) and is a much simpler and more precise way of predicting cancer. It is especially useful in cases of breast and prostate cancer where operations can be avoided in initial treatment. The potential benefits of using uPAR to detect cancer are enormous. Indeed, Curasight currently leads the global market in the use of this technology.

Visit website
Pitch your idea